Fortress Biotech, based in Bay Harbor Islands, Florida, specializes in novel pharmaceuticals with seven marketed products and over 25 developmental programs across oncology, rare diseases, and gene therapy. The company went public in November 2011 and has 186 employees.
Fortress Biotech (FBIO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Fortress Biotech's actual EPS was -$0.50, missing the estimate of -$0.37 per share, resulting in a -36.17% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
